Veran Medical Technologies announced today that it has recently completed its first installation and performed several procedures at Duke University Medical Center with its FDA-cleared SPiN Drive™ product. The product enables clinicians to navigate deep into the peripheral regions of the lungs to access, biopsy and treat potentially cancerous Solitary Pulmonary Nodules (SPN's).
"I am pleased with how accurate, fast, and easy to use the SPiN Drive system is," said Momen Wahidi, MD, Director of Interventional Pulmonology and Bronchoscopy at Duke University Medical Center.
"Performing these procedures at Duke marks a significant milestone in the company's history," said Jerome R. Edwards, Veran president and chief executive officer.
"We feel confident that our product provides the needed accuracy and streamlined workflow to truly enable pulmonologists to diagnose and treat lung cancer in a manner that makes a significant impact," said Troy L. Holsing, Veran chief technology officer.
Lung Cancer is a deadly disease that mortally claims 85% of patients within five years. Diagnosing lung cancer at Stage 1 improves survival chances significantly. Due to the 69 million CT Scans that occur annually in the United States, inadvertent lung cancer screening is occurring. However, SPN's in the peripheral lung are inaccessible with today's techniques and technologies, leaving patients on "watchful waiting" protocols of repeat CT Scanning for years on end causing significant patient anxiety and unproductive costs added to the U.S. healthcare system. Veran's SPiN Drive product acts as a GPS-like system to enable pulmonologists and surgeons to access these SPN's to immediately diagnose malignancy, stop the "watchful waiting" and reduce Healthcare Spending.
Breast cancer survivors at higher risk of developing second cancers